@article{oai:soar-ir.repo.nii.ac.jp:00003752, author = {Shigemura, Tomonari and Yamazaki, Takashi and Hara, Yosuke and Ou, Jing-Ni and Stevens, Anne M and Ochs, Hans D and Koike, Kenichi and Agematsu, Kazunaga}, journal = {PEDIATRIC RHEUMATOLOGY}, month = {Jul}, note = {Systemic juvenile idiopathic arthritis (sJIA) is a systemic inflammatory disease characterized by arthritis, spiking fever and a skin rash that is frequently complicated by macrophage activation syndrome (MAS), a life-threatening disorder. We report a 22-month-old girl with sJIA who developed severe MAS but was successfully treated with corticosteroids, cyclosporin A, and non-steroidal anti-inflammatory drugs by monitoring serum IL-18 levels. IL-18 is an extremely useful cytokine for monitoring the activity of sJIA and MAS, and serum IL-18 can be used as an indicator for the effectiveness of treatment and the decision to discontinue therapy., Article, PEDIATRIC RHEUMATOLOGY. 9:15 (2011)}, title = {Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome}, volume = {9}, year = {2011} }